Charles Schwab Investment Management Inc. increased its stake in shares of Humacyte, Inc. (NASDAQ:HUMA – Free Report) by 7.5% during the 4th quarter, Holdings Channel.com reports. The fund owned 775,718 shares of the company’s stock after purchasing an additional 54,400 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Humacyte were worth $3,917,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. State Street Corp increased its position in shares of Humacyte by 66.1% during the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock worth $25,917,000 after purchasing an additional 1,895,529 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Humacyte during the 3rd quarter worth approximately $596,000. Thrivent Financial for Lutherans acquired a new position in Humacyte during the third quarter worth approximately $712,000. Barclays PLC lifted its stake in Humacyte by 177.6% in the third quarter. Barclays PLC now owns 236,742 shares of the company’s stock valued at $1,288,000 after buying an additional 151,458 shares during the last quarter. Finally, Brookstone Capital Management acquired a new stake in shares of Humacyte in the fourth quarter valued at approximately $56,000. 44.71% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Humacyte in a report on Wednesday, March 12th. D. Boral Capital restated a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research note on Wednesday. Finally, Benchmark reiterated a “buy” rating on shares of Humacyte in a research note on Thursday, February 27th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Humacyte has a consensus rating of “Buy” and a consensus target price of $13.71.
Humacyte Price Performance
NASDAQ:HUMA opened at $2.00 on Thursday. The firm has a market cap of $251.72 million, a price-to-earnings ratio of -1.49 and a beta of 1.36. The firm’s fifty day moving average price is $3.71 and its 200 day moving average price is $4.55. Humacyte, Inc. has a 1-year low of $1.96 and a 1-year high of $9.97.
About Humacyte
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Further Reading
- Five stocks we like better than Humacyte
- What is the Nikkei 225 index?
- Energy Transfer: Powering Data With Dividends and Diversification
- Stock Analyst Ratings and Canadian Analyst Ratings
- Qualcomm Stock Is Coiling for a Breakout
- EV Stocks and How to Profit from Them
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Want to see what other hedge funds are holding HUMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humacyte, Inc. (NASDAQ:HUMA – Free Report).
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
